vTv Therapeutics (NASDAQ:VTVT) Price Target Raised to $57.00

vTv Therapeutics (NASDAQ:VTVT) had its target price raised by BTIG Research from $49.00 to $57.00 in a report issued on Thursday morning, MarketBeat.com reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other equities analysts have also recently issued reports on VTVT. Weiss Ratings upgraded vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a report on Monday, May 18th. Zacks Research cut vTv Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Rodman & Renshaw initiated coverage on vTv Therapeutics in a research report on Tuesday, June 30th. They issued a “buy” rating and a $67.00 target price for the company. Finally, Wall Street Zen raised vTv Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $56.67.

vTv Therapeutics Stock Performance

vTv Therapeutics stock opened at $32.88 on Thursday. vTv Therapeutics has a fifty-two week low of $14.00 and a fifty-two week high of $44.00. The stock has a market cap of $129.55 million, a P/E ratio of -35.35 and a beta of 0.25. The firm’s fifty day moving average price is $33.97 and its 200-day moving average price is $35.48.

vTv Therapeutics (NASDAQ:VTVT) last announced its earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $1.44. The company had revenue of $36.84 million during the quarter, compared to analysts’ expectations of $20.00 million. On average, analysts predict that vTv Therapeutics will post -2.19 earnings per share for the current year.

Institutional Trading of vTv Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. purchased a new stake in vTv Therapeutics during the fourth quarter valued at about $221,000. Geode Capital Management LLC increased its holdings in shares of vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after buying an additional 12,896 shares during the period. Finally, 683 Capital Management LLC purchased a new position in shares of vTv Therapeutics in the fourth quarter worth about $731,000. 17.51% of the stock is owned by institutional investors.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.